Ken Goldman, formerly senior equity analyst at Lehman Brothers, has joined Stockton Partners of New York, a privately funded private-equity investment firm, as executive vice president and chief investment officer. Goldman covered the genomics sector as an analyst for Lehman for five years.
George Dunbar joins Quantum Dot of Hayward, Calif., as chief executive officer and director, replacing company founder Joel Martin, who will remain chairman of the company’s board. Dunbar previously was CEO of Targesome, an early-stage targeted drug delivery start-up. He also served as CEO of Epic Therapeutics, a controlled release formulation company sold to Baxter Healthcare in 2002. He’s also held board and management positions at Molecular Probes, Amersham, and Ares Serono. Dunbar also serves on the business advisory board of Ultreia Capital in Zurich, Switzerland, and is an outside director with Competitive Technologies, Sonus Pharmaceuticals, and the Valley Medical Center Foundation in San Jose.
Mark Kay, professor of pediatrics and genetics, and director of the program in human gene therapy at Stanford University School of Medicine, has joined the scientific advisory board of the CombiMatrix life sciences unit of Acacia Research, the company said this week. Kay is a pioneer in areas including RNAi, gene and nucleic-acid drug delivery, and gene therapy. Most notably, he was the first to develop and to demonstrate the efficacy of siRNA in mammals.
Karin Eastham will resign as senior vice president and chief financial officer of Diversa, effective May 14, the company announced last week. Eastman will continue to consult for Diversa for an undetermined period of time to ease the transition.
David Palmer moves to chief operating officer from vice president of business development for the Pittsburgh Life Sciences Greenhouse. Previously, he was CEO of UK firm Confirmant. Palmer holds a master's degree in public management from Carnegie Mellon University.